Patent intelligence · US
US 9833479
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
Patent details — US 9833479
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2017
- Expiration
- Nov 30, 2037
- Applicant
- Sangamo Therapeutics, Inc.
- Claims
- 9
- CPC classes
- A61K, A61K2035/124, A61K35/12, A61K35/28
Quick answer
US 9833479 (Gene correction of SCID-related genes in hematopoietic stem and progenitor cells) is held by Sangamo Therapeutics, Inc.. Status: granted. Granted Dec 5, 2017. Expires Nov 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2035/124, A61K35/12, A61K35/28, A61K35/545, A61K38/1709
More from Sangamo Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12318427
Methods and compositions for modulation of tau proteins
granted -
US 12139517
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
granted -
US 12043650
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
granted -
US 11981967
Engineering AAV
granted -
US 11981739
Chimeric antigen receptor specific for interleukin-23 receptor
granted -
US 11920169
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 11898158
Methods and compositions for the treatment of lysosomal storage diseases
granted -
US 11884930
Method of inactivating a glucocorticoid receptor gene in an isolated cell
granted
Frequently asked questions
What is US patent 9833479?
US 9833479 (Gene correction of SCID-related genes in hematopoietic stem and progenitor cells) is held by Sangamo Therapeutics, Inc.. Status: granted. Granted Dec 5, 2017. Expires Nov 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9833479?
Sangamo Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 192 pharmaceutical patents for this assignee.
When does US 9833479 expire?
Our index shows an expiration date of Nov 30, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.